Table 4. Aspirin Use, Statin Use, and Statin Adherence Among Patients With Extremely Premature Atherosclerotic Cardiovascular Disease.

Variable	No. (%)		Adjusted OR/β coefficient (95% CI)c	P value
	Patients with extremely premature ASCVD (n = 7716)a	Patients with nonpremature ASCVD (n = 1 112 455)b
Aspirin used	3668 (47.5)	860 726 (77.4)	0.27 (0.26 to 0.29)d	<.001
Statin use
Any	3523 (45.7)	894 931 (80.5)	0.25 (0.24 to 0.27)c	<.001
High-intensity	1755 (22.7)	332 820 (29.9)	0.78 (0.74 to 0.82)c	<.001
Statin PDC
≥0.8	1830 (51.9)	644 357 (72.0)	0.44 (0.41 to 0.47)c	<.001
Mean (SD)	0.64 (0.36)	0.80 (0.29)	−0.15 (−0.16 to −0.14)	<.001

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; OR, odds ratio; PDC, proportion of days covered.

^aPatients with extremely premature ASCVD were those who experienced their first ASCVD event before age 40 years.

^bPatients with nonpremature ASCVD were those who experienced their first ASCVD event at age 55 years or older for men and age 65 years or older for women.

^cAdjusted for sex, race/ethnicity, obesity (body mass index ≥30 [calculated as weight in kilograms divided by height in meters squared]), hypertension, diabetes, type of ASCVD (ischemic heart disease vs peripheral arterial disease vs ischemic cerebrovascular disease), clinician type (physician vs advanced practice practitioner), teaching vs nonteaching facility, urban vs rural facility, number of cardiology visits 12 months before index primary care physician (PCP) visit, median number of PCP visits 12 months before index PCP visit, median number of days from first ASCVD event to the index PCP visit, and Diagnostic Cost Group relative risk score.

^dRegression model for aspirin use was adjusted for nonaspirin platelet use and anticoagulant use in addition to all of the aforementioned covariates.